Skip to main content
ABVC BIOPHARMA, INC. logo

ABVC BIOPHARMA, INC. — Investor Relations & Filings

Ticker · ABVC ISIN · US00091F1066 US Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2017-06-20 Regulatory Filings
Country US United States of America
Listing US ABVC

About ABVC BIOPHARMA, INC.

https://abvcpharma.com/

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes drugs and medical devices to address unmet medical needs. The company focuses on advancing a pipeline of botanical, plant-based pharmaceuticals and medical technologies sourced from research institutions. Its therapeutic areas of focus include oncology, ophthalmology, and central nervous system disorders such as major depressive disorder (MDD) and adult attention-deficit/hyperactivity disorder (ADHD). Key products in development include Vitargus®, a biodegradable vitreous substitute for eye surgery, and botanical drug candidates for MDD and ADHD. Additionally, its subsidiary, BioKey, Inc., offers contract development and manufacturing services for nutritional and pharmaceutical products.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2017
Regulatory Filings
2017-06-20 English
Regulatory Filings 2017
Regulatory Filings
2017-06-15 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filing with the SEC, which is a Current Report used to announce significant events or other material information that occurs between periodic reports. The text describes a co-development agreement entered into by the company, including financial terms and forward-looking statements. It does not contain comprehensive financial statements or detailed financial performance data typical of Annual Reports (10-K) or Interim Reports (IR). It is not an earnings release or a management discussion. The document is not a proxy statement, nor does it relate to board changes or voting results. The content is an announcement of a material event (a co-development agreement) and thus fits the category of Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings like Form 8-K that do not fit other specific categories. The document length is 4523 characters, which is consistent with a typical 8-K filing. Therefore, the appropriate classification is Regulatory Filings (RNS).
2017-05-30 English
AMENDMENT NO. 3 TO REGISTRATION STATEMENT
Capital/Financing Update Classification · 100% confidence The document is an Amendment No. 3 to a Form S-1 Registration Statement filed with the SEC under the Securities Act of 1933. It includes detailed information about the registration of securities for resale, the company background, risk factors, management discussion, and other disclosures typical of a registration statement for an initial public offering or resale offering. The presence of SEC form references (Form S-1), registration fee calculations, and offering details clearly identify this as a capital raising filing. This is not an annual report, earnings release, or other financial report but a regulatory filing related to capital markets and securities registration. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is the filing itself, not just an announcement or certification.
2017-05-24 English
Annual Report 2017
Annual Report Classification · 95% confidence The document is a detailed response letter from American BriVision (Holding) Corporation to the U.S. Securities and Exchange Commission (SEC) staff regarding comments on their Registration Statement on Form S-1 and an amended Form 10-K. The letter addresses specific SEC comments on risk factors, business disclosures, clinical trials, executive compensation, related party transactions, and financial statements. It references Amendment No. 3 to the Registration Statement and 10-K/A No. 2, indicating that the company is providing detailed revisions and clarifications to previously filed documents. The presence of extensive discussion on financial statements, auditor's reports, and fiscal year data confirms this is related to an Annual Report filing. The document is not merely an announcement or certification but contains substantive content related to the annual report and registration statement amendments. Therefore, the filing type is Annual Report (10-K).
2017-05-24 English
AMENDMENT NO.2 TO ANNUAL REPORT
Annual Report FY 2016
2017-05-22 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.